Archives
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
There have been two reports of tumor shrinkage
2020-11-28

There have been two reports of tumor shrinkage in response to dasatinib treatment in lung SCC patients harboring the DDR2 kinase domain S768R mutation., In the first case described by Hammerman et al. a combination of erlotinib (an epithelial growth factor receptor inhibitor) and dasatinib was admin
-
NG25 Films treated with Diaz ES VWFIIINle but
2020-11-28

Films treated with Diaz-ES-VWFIIINle but not exposed to UV light supported only slight platelet deposition, suggesting that passively-bound peptides were removed under shear. However, treatment with Diaz-ES-VWFIIINle and UV restored platelet surface coverage to about 50% of the level on native colla
-
In order to assess quantitatively
2020-11-28

In order to assess quantitatively the contribution of the ung, dug and dut EPZ015666 synthesis to uracil-DNA accumulation in E. coli, we have developed a novel method for measuring uracil residues in DNA that is based on the approach of Kow and co-workers [33] for measuring AP-sites in DNA. The meth
-
2-Palmitoylglycerol br Additional CDKs with a role in cancer
2020-11-28

Additional CDKs with a role in cancer Small molecule CDK inhibitors The majority of protein kinase inhibitors developed to date are type I inhibitors: they bind at the ATP–binding site, are ATP-competitive and target the kinase in its active state; with the activation loop DFG motif in the ‘in
-
Based on the finding described above the present study
2020-11-28

Based on the finding described above, the present study was designed to investigate the effects of specific CRF receptors, CRF1 and CRF2, in the BLA and CeA on the duration of TI in guinea pigs (Cavia porcellus). To this end, we evaluated whether administration of the CRF1 MLN0128 synthesis antagon
-
Several studies have described the role of NP
2020-11-28

Several studies have described the role of NP in vRNP nuclear export. For example, leptomycin B (LMB), an inhibitor of the CRM1 nuclear export signal (NES) binding domain (Kudo et al., 1999), inhibits nuclear export of vRNP and NP, but not NEP or M1, in virally infected or transfected Benzamil (Elto
-
br Experimental procedures br Introduction Perfluorooctane s
2020-11-28

Experimental procedures Introduction Perfluorooctane sulfonate (PFOS) is an anthropogenic compound with high thermal, chemical and biological stability, which makes it a perfect ingredient for many industrial applications (Kissa, 2001). Nevertheless, these characteristics also mean that PFOS i
-
Magnified regions of the upregulated proteins
2020-11-28

Magnified regions of the upregulated proteins identified by MALDI-TOF are shown in Fig. 2. The identified proteins were phosphoglycerate kinase, fructose-bisphosphate aldolase class II, alcohol dehydrogenase, phosphoglyceromutase, 6-phosphogluconolactonase, malate dehydrogenase, alkyl hydroperoxide
-
In the literature we can find two different modes
2020-11-27

In the literature, we can find two different modes of action for estrogens: Firstly there is the commonly accepted genomic pathway. Estrogens pass the cell membrane due to their lipophilic character via diffusion and bind to estrogen receptors (ERs) in the cytoplasm. After binding a dimerization of
-
Identification of the drug to be
2020-11-27

Identification of the drug to be used as first-step antihypertensive treatment has always been, and remains, a matter of debate. The decision wihich drug (or drug combination) to choose as first-line therapy depend on many variables such as coexisting metabolic disorders, obesity, presence of subcli
-
br STAR Methods br Acknowledgments We
2020-11-27

STAR★Methods Acknowledgments We thank members of R.L. lab and F. Schweisguth for critical reading of the manuscript. We are also grateful to F. Janody, M. Miura, C. Bökel, H.D. Ryoo, G. Jiménez, the Bloomington Drosophila Stock Center, the Drosophila Genetic Resource Center, the Vienna Drosoph
-
Four m thick sections of formalin fixed
2020-11-27

Four-μm thick sections of formalin-fixed paraffin-embedded tissue samples from uterine cervical cancers were cut with a microtome and dried overnight at 37 °C on a silanized-slide (Dako, Carpentaria, CA, USA). The protocol of the universal Dako Labeled Streptavidin–Biotin kit (Dako) was followed for
-
Considering these reports and with the aim of further
2020-11-27

Considering these reports, and with the aim of further investigating the mechanism by which the cAMP-Epac/PKA pathway activates eNOS, we have performed imaging experiments evaluating the effect of drugs that increase cAMP or modify its signalling pathways (PKA or Epac activators and inhibitors) on b
-
In addition to the ESIs identified that
2020-11-27

In addition to the ESIs identified that target both EPAC1 and EPAC2, ESI-05 and ESI-07 were identified as compounds that selectively antagonise EPAC2, displaying almost no inhibition of EPAC1 at concentrations up to 100μM [99]. Both compounds were effective inhibitors EPAC2 GEF activity towards Rap1
-
N Cyclopentylmethyl analog exhibited fold less potent recept
2020-11-27

N-Cyclopentylmethyl analog 25 exhibited 2.3-fold less potent receptor affinity and 1.6-fold less potent antagonist activity. Among the compounds tested, the N-isobutyl analog 23 showed the most potent EP1 receptor affinity and antagonist activity. In summary, a series of 4-( 2-[alkyl(phenylsulfonyl
15847 records 730/1057 page Previous Next First page 上5页 726727728729730 下5页 Last page